Astellas/Pfizer’s COX-2 Inhibitor Celecox Gains Additional Indications In Japan
This article was originally published in PharmAsia News
Executive Summary
Astellas Pharma and Pfizer Japan June 17 announced additional indications for their COX-2 inhibitor Celecox (celecoxib) in Japan for lumbago, scapulohumeral periarthritis, cervico-omo-brachial syndrome and tendinitis/tendosynovitis
You may also be interested in...
Lured By Rising Transplant Cases, Astellas Finally Brings Prograf To India
MUMBAI - Japan's second-largest drug maker Astellas is bringing into India its flagship organ transplant drug Prograf (tacrolimus) in a bid to tap the Asian giant's steadily growing domestic pharmaceutical market. The product registration application for Prograf is pending with the Drug Controller General of India and Astellas hopes to launch the drug by the end of the current financial year
Lured By Rising Transplant Cases, Astellas Finally Brings Prograf To India
MUMBAI - Japan's second-largest drug maker Astellas is bringing into India its flagship organ transplant drug Prograf (tacrolimus) in a bid to tap the Asian giant's steadily growing domestic pharmaceutical market. The product registration application for Prograf is pending with the Drug Controller General of India and Astellas hopes to launch the drug by the end of the current financial year
Daiichi Sankyo Seeking Small Biotech Acquisitions In Europe
Daiichi Sankyo is scanning Europe for potential acquisitions that would help the Japanese company expand its market reach and enhance its product pipeline. Daiichi will focus on smaller biotechnology companies that have a strong oncology focus and a promising pipeline